Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.19, $0.02 better than the analyst estimate of $0.17. Revenue for the quarter came in at $131.5 million versus the consensus estimate of $129.85 million.

GUIDANCE:

Revenue milestones under the AbbVie agreement for 2019 are expected to be $20 million contingent on FDA's acceptance of the NDA submission of elagolix for uterine fibroids. Ongoing SG&A and R&D expenses for 2019, excluding upfront expenses associated with the recently announced Voyager Therapeutics collaboration, should approximate $550 to $600 million. The 2019 anticipated expenses include an estimated $80 million of share-based compensation expense. The increase in expenses is largely attributable to the Voyager collaboration\'s ongoing program costs, increased investment in INGREZZA patient education, sales and marketing activities, opicapone NDA submission and increased R&D pipeline activities.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.